Key terms
About TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TNXP news
Mar 25
9:12am ET
Tonix Pharma Earns FDA Pediatric Designation Amid Risks
Mar 25
8:25am ET
Tonix Pharmaceuticals receives Rare Pediatric Disease designation for TNX-2900
Mar 21
9:33am ET
Tonix Pharma Reveals Innovative Oxytocin Research Advancements
Mar 21
8:15am ET
Tonix Pharmaceuticals announces presentation at ACS of next-gen oxytocin
Mar 20
10:02am ET
Tonix Pharma Readies for Tonmya™ U.S. Launch and Production
Mar 20
8:04am ET
Tonix selects two contract manufacturing organizations for launch of Tonmya
Mar 19
8:22am ET
Tonix Pharma Announces Full Integration and Future Plans
Mar 19
8:13am ET
Tonix announces transition to fully integrated biopharmaceutical company
Mar 11
8:23am ET
Tonix Pharma’s Tonmya Shows Promise in Fibromyalgia Study
Mar 11
8:08am ET
Tonix Pharmaceuticals presents additional efficacy data from RESILIENT
Mar 07
8:23am ET
Tonix Pharma’s TNX-102 SL Shows Promise for PTSD Treatment
Mar 07
8:18am ET
Tonix Pharmaceuticals announces publication on TNX-102 SL
Mar 06
8:22am ET
Tonix Pharma: Anticipating Tonmya’s Impact on Fibromyalgia Treatment
Mar 06
8:12am ET
Tonix Pharmaceuticals selectes EVERSANA to support launch strategy of Tonmya
Mar 05
8:22am ET
Tonix announces translation of preclinical PK parameters of TNX-1500
Mar 05
8:22am ET
Tonix Pharma Advances with Promising TNX-1500 Studies
Feb 28
8:23am ET
Tonix Pharma Advances TNX-1500 Trial, Cautions Investors
Feb 28
8:04am ET
Tonix Pharmaceuticals completes clinical stage of Phase 1 trial for TNX-1500
Feb 27
8:22am ET
Tonix Pharma Expands Asian Market Reach with Tonmya™ Study
Feb 27
8:18am ET
Tonix Pharmaceuticals announces results from clinical PK study of Tonmya
Feb 15
5:12pm ET
Tonix Pharma Shareholders Approve Strategic Financing Moves
Feb 15
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Feb 14
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Feb 14
8:24am ET
Tonix Pharmaceuticals hosted KOL webinar on Phase 3 fibromyalgia trial
Feb 13
8:22am ET
Tonix Pharma Advances Tonmya™ with New FDA Application Partner
Feb 12
8:19am ET
Tonix Pharma Receives FDA Nod, Updates Investor Presentation
Feb 12
8:04am ET
Tonix Pharmaceuticals announces FDA IND clearance for trial of TNX-102 SL
Jan 31
7:08am ET
Tonix Pharmaceuticals announces research on pre-existing pain conditions, COVID
Jan 26
4:28am ET
Tonix Pharma Shareholders Approve Expansion of Shares
Jan 26
4:27am ET
Tonix Pharma Expands Authorized Stock Capacity
Jan 09
7:08am ET
Tonix Pharmaceuticals presents additional data from TNX-203 SL
No recent news articles are available for TNXP
No recent press releases are available for TNXP
TNXP Financials
Key terms
Ad Feedback
TNXP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TNXP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range